← Leaderboards
Richard C Mulligan
Dana-Farber Cancer Institute
$9,008,855
Attributed
$9,008,855
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–16$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$9,008,855 · 9
By mechanism
P30$3,229,699 · 3
R01$2,965,343 · 2
P50$1,848,010 · 3
RC1$965,803 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Edward J Benz$50,055,526
- Pamela A. Silver$12,660,360
- Alan N. Engelman$40,161,770
- Wen-Shu Wu$5,750,738
- Robert J Gray$106,917,463
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyTechnologyGene TransferVectorProductionAreaResearch PersonnelViral VectorGenesNeoplastic CellPlasmidsCell LineMethod DevelopmentGene ExpressionCancer CenterServicesReagentGene Transduction AgentProgramsTransfectionEngineeringMediatingLentivirus VectorBase
Grant awards (28)
Vector$240,103
P30 · FY2016 · CA · contact PI
Vector$240,341
P30 · FY2015 · CA · contact PI
Vector$229,063
P30 · FY2014 · CA · contact PI
Vector$221,194
P30 · FY2013 · CA · contact PI
Vector$239,829
P30 · FY2012 · CA · contact PI
Engineered in vivo nuclear fusion: application to regenerative medicine$489,618
RC1 · FY2010 · DK · contact PI
Core - Vector$460,968
P30 · FY2010 · CA · contact PI
Improving the Safety Profile of Lentiviral Vectors$318,830
R01 · FY2010 · GM · contact PI
Engineered in vivo nuclear fusion: application to regenerative medicine$476,185
RC1 · FY2009 · DK · contact PI
Core - Vector$473,649
P30 · FY2009 · CA · contact PI
Improving the Safety Profile of Lentiviral Vectors$321,971
R01 · FY2009 · GM · contact PI
Core - Vector$433,802
P30 · FY2008 · CA · contact PI
Exogenous Gene Control via Modulation of RNA Self-Cleavage$414,079
R01 · FY2008 · GM · contact PI
Improving the Safety Profile of Lentiviral Vectors$321,100
R01 · FY2008 · GM · contact PI
Core - Vector$454,270
P30 · FY2007 · CA · contact PI
Exogenous Gene Control via Modulation of RNA Self-Cleavage$416,192
R01 · FY2007 · GM · contact PI
Improving the Safety Profile of Lentiviral Vectors$321,100
R01 · FY2007 · GM · contact PI
Exogenous Gene Control via Modulation of RNA Self-Cleavage$418,369
R01 · FY2006 · GM · contact PI
Core - Vector$236,480
P30 · FY2006 · CA · contact PI
Exogenous Gene Control via Modulation of RNA Self-Cleavage$433,702
R01 · FY2005 · GM
NOVEL APPLICATION OF STEM CELLS/ RETROVIRAL VECTORS$284,242
P50 · FY2002 · HL
NOVEL APPLICATION OF STEM CELLS/ RETROVIRAL VECTORS$284,242
P50 · FY2001 · HL
CORE--SHARED VECTOR FACILITY$219,976
P50 · FY2001 · HL
SUSTAINED/TARGETED TRANSGENE EXPRESSION--DEVELOPMENT OF NEW VIRAL VECTOR SYSTEMS$219,976
P50 · FY2001 · HL
NOVEL APPLICATION OF STEM CELLS/ RETROVIRAL VECTORS$284,242
P50 · FY2000 · HL
CORE--SHARED VECTOR FACILITY$277,666
P50 · FY2000 · HL
SUSTAINED/TARGETED TRANSGENE EXPRESSION--DEVELOPMENT OF NEW VIRAL VECTOR SYSTEMS$277,666
P50 · FY2000 · HL
CORE--VECTOR$0
P30 · FY2000 · CA